A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone

Overview

The purpose of this study is to assess the pharmacokinetic profiles of tolcapone in healthy subjects after administration of one or two oral doses of multiple modified release prototype formulations.

Full Title of Study: “A Phase 1, Single-Part, 6-Period, Sequential, Non-Randomized, Open-Label Study Designed to Evaluate the Pharmacokinetic Profile of Tolcapone Following Administration of Modified Release Prototype Formulations and an Experimental Divided Dose Regimen in Healthy Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 22, 2018

Interventions

  • Drug: Tolcapone
    • Multiple doses of tolcapone tablets in the fasted state
  • Drug: Tolcapone Modified Release Prototype
    • A single dose of tolcapone modified release prototype in the fasted state
  • Drug: Tolcapone Divided Dose
    • Tolcapone (suspension) in equal divided doses in the fasted state
  • Drug: Tolcapone Modified Release Prototype
    • A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)

Arms, Groups and Cohorts

  • Experimental: Modified Release Prototypes of Tolcapone

Clinical Trial Outcome Measures

Primary Measures

  • Pharmacokinetic Assessment: Time to maximum concentration (Tmax)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Time to maximum concentration (Tmax)
  • Pharmacokinetic Assessment: Maximum observed concentration (Cmax)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Maximum observed concentration (Cmax)
  • Pharmacokinetic Assessment: Area under the curve (AUC)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Area under the curve (AUC)
  • Pharmacokinetic Assessment: Plasma half-life (t1/2)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Plasma half-life (t1/2)
  • Pharmacokinetic Assessment: Relative bioavailability (Frel)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Relative bioavailability (Frel)

Secondary Measures

  • Pharmacokinetic Assessment of 3-O-Methyltolcapone: Time to maximum concentration (Tmax)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Time to maximum concentration (Tmax)
  • Pharmacokinetic Assessment of 3-O-Methyltolcapone: Maximum observed concentration (Cmax)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Maximum observed concentration (Cmax)
  • Pharmacokinetic Assessment of 3-O-Methyltolcapone: Area under the curve (AUC)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Area under the curve (AUC)
  • Pharmacokinetic Assessment of 3-O-Methyltolcapone: Plasma half-life (t1/2)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Plasma half-life (t1/2)
  • Pharmacokinetic Assessment of 3-O-Methyltolcapone: Relative Bioavailability (Frel)
    • Time Frame: Pre-dose to 24 hours post-dose
    • Relative Bioavailability (Frel)
  • Number of subjects reporting treatment-related Adverse Events (AEs)
    • Time Frame: Screening to 10 days following last dose
    • Abnormalities in safety laboratory tests, vital signs, electrocardiogram, physical examination that meet the protocol definition will be captured as AEs

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy males or non-pregnant, non-lactating healthy females – Age 18 to 65 years of age at the time of signing informed consent – Body mass index (BMI) of 18.0 to 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator – Must be willing and able to communicate and participate in the whole study – Must provide written informed consent – Must agree to use an adequate method of contraception Exclusion Criteria:

  • Subjects who have received any IMP in a clinical research study within the previous 3 months prior to first dose. – Subjects who are study site employees, or immediate family members of a study site or sponsor employee. – Subjects who have previously been enrolled in this study. – History of any drug or alcohol abuse in the past 2 years. – Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening – Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months – Females of childbearing potential who are pregnant or lactating – Subjects who do not have suitable veins for multiple venepunctures / cannulation as assessed by the investigator at screening – Clinically significant abnormal biochemistry, hematology or urinalysis as judged by the investigator – Hemoglobin below the lower limit of normal – ALT or AST outside the normal reference range at screening or admission. – Confirmed positive drugs of abuse test result – Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results – History of clinically significant cardiovascular, neurological, renal, hepatic, chronic respiratory or gastrointestinal disease, or psychiatric disorder, as judged by the investigator – Subjects with a history of cholecystectomy or gall stones – Serious adverse reaction or serious hypersensitivity to any drug, the formulation excipients, or lactose intolerance – Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. – Donation or loss of greater than 400 mL of blood within the previous 3 months – Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies in the 14 days before IMP administration. – Contraindication for Tasmar® – Failure to satisfy the investigator of fitness to participate for any other reason NOTE: Other inclusion/exclusion criteria may apply, per protocol

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Corino Therapeutics, Inc.
  • Collaborator
    • Quotient Sciences
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Litza McKenzie, Principal Investigator, Quotient Sciences

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.